

WOAH Reference Laboratory Reports Activities 2025

This report has been submitted: 22 janvier 2026 16:43

LABORATORY INFORMATION

*Name of disease (or topic) for which you are a designated WOAHO Reference Laboratory:	Infectious bursal disease
*Address of laboratory:	Anses - 41 route de Beauce-main - BP53 - 22440 - Ploufragan - France
*Tel:	+33 (0)2 96 01 62 22
*E-mail address:	nicolas.etteradossi@anses.fr
Website:	https://www.anses.fr/fr/content/laboratoire-de-ploufragan-plouzane-niort
*Name (including Title) of Head of Laboratory (Responsible Official):	Dr Nicolas ETERRADOSSI
*Name (including Title and Position) of WOAHO Reference Expert:	Dr Nicolas ETERRADOSSI, Director
*Which of the following defines your laboratory? Check all that apply:	Governmental

TOR1: DIAGNOSTIC METHODS

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in WOAHO Manual (Yes/No)	Total number of test performed last year	
		Nationally	Internationally
Indirect diagnostic tests			
AGID	Yes	1361	0
Virus neutralization	Yes	382	0
Direct diagnostic tests			
Viral isolation or titration on Chicken Embryo Fibroblasts	Yes	59	0
Viral isolation or titration on chicken B cells	No	597	0
Partial amplification of IBDV genome (RT-PCR for VP2 or VP1)	Yes	56	0
Detection of IBDV genome (rtRT-PCR)	No	115	0
Complete IBDV genome sequencing (Sanger or NGS)	No	34	0

TOR2: REFERENCE MATERIAL

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by WOAHO?

3. Did your laboratory supply standard reference reagents (nonWOAH-approved) and/or other diagnostic reagents to WOA Members?

No

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to WOA Members?

TOR3: NEW PROCEDURES

6. Did your laboratory develop new diagnostic methods for the designated pathogen or disease?

No

7. Did your laboratory validate diagnostic methods according to WOA Standards for the designated pathogen or disease?

No

8. Did your laboratory develop new vaccines for the designated pathogen or disease?

9. Did your laboratory validate vaccines according to WOA Standards for the designated pathogen or disease?

TOR4: DIAGNOSTIC TESTING FACILITIES

10. Did your laboratory carry out diagnostic testing for other WOA Members?

Yes

Name of WOA Member Country seeking assistance	Date	Which diagnostic test used	No. samples received for provision of diagnostic support	No. samples received for provision of confirmatory diagnoses
FRANCE	2025-03-15	Sequencing and genotyping	0	1

11. Did your laboratory provide expert advice in technical consultancies on the request of an WOA Member?

Yes

Name of the WOA Member Country receiving a technical consultancy	Purpose	How the advice was provided
AUSTRALIA	Exchanges on IBDV virus isolation procedure	email
GERMANY	Diagnostic kit development and transfer of IBDV ref materials (non WOA approved)	email, videoconference
IRAN	Scientific advice for reference antiserum preparation	email
UNITED STATES OF AMERICA	Exchanges and advices on production of viruses by reverse genetics and on preparation of viral stocks	email, videoconference
UNITED STATES OF AMERICA	Exchanges on transfer of IBDV materials	email
FRANCE	provision of reagents (AGID antigen, non WOA approved)	email

TOR5: COLLABORATIVE SCIENTIFIC AND TECHNICAL STUDIES

12. Did your laboratory participate in international scientific studies in collaboration with WOA Members other than the own?

13. In exercising your activities, have you identified any regulatory research needs* relevant for WOA?

No

TOR6: EPIZOOLOGICAL DATA

14. Did your Laboratory collect epidemiological data relevant to international disease control?

15. Did your laboratory disseminate epidemiological data that had been processed and analysed?

16. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category and list the details in the box)

a) Articles published in peer-reviewed journals:

1

Le Nouën C., Courtillon C., Soubies S.M., Cruz P., Dolan M.A., Toquin T., Macaigne M., Amelot M., Keita A., Müller H., Härtle S., Etteradossi N. An amino acid insertion in the PHI loop of the VP2 capsid protein of serotype 1 infectious bursal disease virus deeply modifies its antigenicity and abrogates its propagation into B cells. Veterinary Research. (Submitted)

b) International conferences:

0

c) National conferences:

0

d) Other (Provide website address or link to appropriate information):

1

Conference on "Immunosuppressive diseases on poultry" and "Infectious Bursal disease" for the professional diploma "Poultry Farm Advisor Training Courses", Avipole Formation, France

TOR7: SCIENTIFIC AND TECHNICAL TRAINING

17. Did your laboratory provide scientific and technical training to laboratory personnel from other WOA Members?

No

TOR8: QUALITY ASSURANCE

18. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)	
ISO17025	see attached file	Compliance certificate ISO 17025 2025.pdf

19. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
Avian Influenza Diagnosis	COFRAC

20. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

Yes

The laboratory quality management system and procedures comply with nationally applicable regulations and cover biorisk (biosafety and biosecurity) evaluation and management, in line with recommendations of chapter 1.1.4 of OIE Manual

TOR9: SCIENTIFIC MEETINGS

21. Did your laboratory organise scientific meetings related to the pathogen in question on behalf of WOA?

No

22. Did your laboratory participate in scientific meetings related to the pathogen in question on behalf of WOA?

No

TOR10: NETWORK WITH WOAHP REFERENCE LABORATORIES

23. Did your laboratory exchange information with other WOAHP Reference Laboratories designated for the same pathogen or disease?

Yes

24. Are you a member of a network of WOAHP Reference Laboratories designated for the same pathogen?

No

25. Did you organise or participate in inter-laboratory proficiency tests with WOAHP Reference Laboratories designated for the same pathogen during the past 2 years?

No

no interlaboratory proficiency testing with other WOAHP reference laboratory for IBD

26. Did your laboratory collaborate with other WOAHP Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

Yes

Title of the project or contract	Scope	Name(s) of relevant WOAHP Reference Laboratories
Revision of WOAHP Manual	IBD chapter	Harbin Veterinary Research Institute, PR China

TOR11: OTHER INTERLABORATORY PROFICIENCY TESTING

27. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than WOAHP Reference Laboratories for the same pathogen during the past 2 years?

Yes

Purpose for inter-laboratory test comparisons ¹	Role of your reference laboratory (organizer/participant)	No. participating laboratories	Name of the test	WOAHP Member Countries
antibody detection in serum	Participant	50	VN test	AUSTRALIA, AUSTRIA, BELGIUM, COLOMBIA, ECUADOR, FRANCE, INDIA, JORDAN, KAZAKHSTAN, NAMIBIA, NEW ZEALAND - PITCAIRN (ISLAND), POLAND, SAUDI ARABIA, SERBIA, SOUTH AFRICA, SPAIN, SWITZERLAND, THAILAND, THE NETHERLANDS, UKRAINE, UNITED ARAB EMIRATES, UNITED KINGDOM, UNITED STATES OF AMERICA, ZAMBIA,
RNA detection in culture medium and chicken bursa tissue samples	Participant	22	real time RT-PCR	AUSTRALIA, COLOMBIA, DENMARK, ECUADOR, FRANCE, GERMANY, JORDAN, MALAYSIA, NEW ZEALAND, PORTUGAL, SAUDI ARABIA, SOUTH AFRICA, THAILAND, THE NETHERLANDS, UKRAINE, UNITED ARAB EMIRATES,

TOR12: EXPERT CONSULTANTS

28. Did your laboratory place expert consultants at the disposal of WOAHP?

Yes

Kind of consultancy	Location	Subject (facultative)
Revision of WOAHP Manual	visio	Revision of IBD chapter

29. Additional comments regarding your report:

Yes

Human resources issues reported on the two previous years have been progressively solved in 2025, and the IBD team has been reconstituted as of end of 2025. We are confident that efforts to strengthen international contacts and interactions started in 2025 can be fully emphasized in 2026. International requests for diagnostic support have been limited and they will be encouraged in 2026.